Table 1.
The distribution of the main driver gene mutation types of patients with lung cancer.
| Type | n = 271 (LUAD) Total (n, %) | n = 227 (LUAD) Total (n, %) | n = 552 (NSCLC) Total (n, %) | n = 153 BM (n, %1/%2) |
|---|---|---|---|---|
| No driven gene mutation | 42 (15.5) | 58 (25.6) | 210 (38.0) | 40 (26.1/19.0) |
| Driver gene mutation | 229 (84.5) | 169 (74.4) | 342 (62.0) | 113 (73.9/33.0) |
| EGFR mutation | 161 (59.4) | 102 (44.9) | 226 (40.9) | 77 (50.3/34.1) |
| KRAS mutation | 20 (7.4) | 22 (9.7) | 55 (10.0) | 12 (7.8/21.8) |
| ALK fusion mutation | 20 (7.4) | 9 (4.0) | 22 (4.0) | 9 (5.9/40.9) |
| RET fusion mutation | 6 (2.2) | 1 (0.4) | 11 (2.0) | 7 (4.6/63.6) |
| ERBB2 mutation | 7 (2.6) | 8 (3.5) | 7 (1.3) | 1 (0.7/14.3) |
| BRAF mutation | 3 (1.1) | 3 (1.3) | 3 (0.5) | 2 (1.3/66.7) |
| MET mutation/amplification | 5 (1.8) | 2 (0.9) | 3 (0.5) | 1 (0.7/33.3) |
| ROS-1 fusion mutation | 6 (2.2) | 3 (1.3) | 3 (0.5) | 0 (0.0/0.0) |
| NRAS mutation | 1 (0.4) | – | – | – |
| PIK3CA/Multiple mutation | – | 3/16 (1.3/7.0) | – | – |
| EGFR mutation +X3 | – | – | 12 (2.2) | 4 (2.6/33.3) |
1Number of brain metastasis/Total number of brain metastasis.
2Number of brain metastasis/Total number of the mutations or total number of no driver gene mutation.
3X genes included the mutations of ALK, KRAS, BRAF, ERBB2, and MET amplifications.
LUAD, lung adenocarcinoma; NSCLC, non-small cell lung cancer; BM, brain metastasis.